Abivax Rebounds, but Obefazimod Unlikely to Replace JAK Inhibitors, Wedbush Says

Wedbush analysts believe that while Abivax's stock has rebounded, its drug obefazimod is unlikely to replace JAK inhibitors in the market. This suggests a cautious outlook on obefazimod's competitive positioning despite recent positive movement for Abivax.